ArticleMolecular oncology2026
Epigenetic silencing of the liver-specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation.
Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
While long noncoding RNAs (lncRNAs) play critical roles in hepatocellular carcinoma (HCC) pathogenesis, the regulatory mechanisms governing liver-specific lncRNAs remain poorly defined. Here, we systematically analyzed staging-specific transcriptomic datasets to identify functionally relevant lncRNAs involved in HCC progression. We identified a liver-specific lncRNA, termed LUNAR (Liver-specific Upregulated Non-coding RNA as Down-Regulator in HCC), reflecting its high expression in normal liver tissue and its functional role in restraining tumor progression in HCC. Analyses across multiple independent patient cohorts revealed that LUNAR expression correlated with clinical outcomes in HCC. Functional assays demonstrated that restoration of LUNAR expression suppressed cell migration, invasion, and in vivo metastasis, without affecting cell proliferation. Mechanistically, LUNAR overexpression was associated with attenuation of NOTCH signaling, while its downregulation in tumors was linked to epigenetic silencing via promoter hypermethylation. Collectively, these findings identify LUNAR as a liver-enriched, epigenetically regulated lncRNA with metastasis-restraining functions. This therefore supports the potential of LUNAR as a tissue-associated biomarker and therapeutic target in HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.